review · Stroke Vascular and Interventional Neurology
The current evidence for thrombolysis’ efficacy beyond the usual treatment window is uncertain. Here, a comprehensive evaluation of the quality of evidence was performed for tenecteplase, a fibrin‐specific thrombolytic agent with a long half‐life, in AIS patients who presented after 4.5 hours from the onset of stroke.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1161/svin.04.suppl_1.257
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
